ADC Therapeutics SA
ANTI-IL13R ALPHA2 ANTIBODIES

Last updated:

Abstract:

This disclosure relates to antibodies that specifically bind to the Interleukin-13 receptor subunit alpha-2 (IL13R.alpha.2) protein, and associated uses and methods for production.

Status:
Application
Type:

Utility

Filling date:

30 Jul 2021

Issue date:

3 Feb 2022